Motesanib is an investigational, orally administered small molecule antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptors, and stem cell factor receptor.
What does EGFR stand for?
EGFR stands for Endothelial Growth Factor Receptor
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of EGFR
We have 24 other meanings of EGFR in our Acronym Attic
- European Group of Financial Institutions
- Export Guarantee Fund of Iran
- Enterprise Growth Fund Limited (Barbados, West Indies)
- Extreme Games Flagging League
- East Gippsland Forest Management Plan (Department of Natural Resources and Environment; Australia)
- Evolutionary Gabor Filter Optimization (vehicle image detection; engineering)
- E-Green Fluorescent Protein (plants)
- Enhanced Green Fluorescent Protein
- Equipment Ground Fault Protection Device
- East Grand Forks Public Library (East Grand Forks, MN)
- Enhanced Growth Factor Receptor
- Epidermal Growth Factor Receptor
- Epidermal Growth Factor Receptor (a kinase enzyme)
- Epidermal Growth Factor Receptor Concentration
- Estimated Glomerular Filtration Rate
- Expression of Growth Factor Receptor (cancer research)
- Epidermal Growth Factor Receptor Tyrosine Kinase
- Epidermal Growth Factor Receptor 1
- Epidermal Growth Factor Receptor Binding Protein
- Epidermal Growth Factor Response Element
Samples in periodicals archive:
About XV-615 XV-615 is novel tyrosine kinase inhibitor with dual activity against the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR).
Academy professor Kari Alitalo and co-workers at the University of Helsinki, Finland, have previously shown that antibodies directed towards vascular endothelial growth factor receptor (VEGFR)-3 can inhibit lymphatic metastasis by 50-70 percent in pre-clinical tumor models.
IMC-1C11 is an investigational monoclonal antibody designed to target and block the Vascular Endothelial Growth Factor Receptor (VEGFR) known as KDR, on the surface of growing endothelial cells.
Scope: - Patient-based forecasts for Exelixis's lead candidate, cabozantinib, supported by key opinion leader research - Assessment of Exelixis's corporate strategy, operating performance, and earlier-stage pipeline Highlights: Exelixis's lead candidate is cabozantinib, an oral inhibitor of the hepatocyte growth factor receptor MET, receptor tyrosine kinase RET, and the vascular endothelial growth factor receptor 2 (VEGFR2).
Vandetanib targets the vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) pathways -- all pathways involved in tumour growth.
Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR.
Painstaking retrospective and prospective analyses of clinical trial data on endothelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) led to European approval in 2010 for AstraZeneca's Iressa across all lines of therapy in patients harboring an activating EGFR mutationseven years after its original filing for use in the wider NSCLC populationwhile Roche/OSI's Tarceva was approved in August 2011 for the first-line treatment of patients with mutant EGFR.